Best Annual GLP-1 Plans: Are the Prepayment Savings Worth It?

Last reviewed: September 8, 2026 Last updated: September 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Annual GLP-1 plans deliver genuine per-month savings—Found's cash-pay annual drops to $169/month from $289 monthly, Calibrate's Metabolic Reset runs $199/month for twelve months, and Henry Meds' 12-month semaglutide plan offers $2,364 paid-in-full versus $3,564 billed monthly—but every prepaid program trades liquidity and exit freedom for those reductions. The central question is not whether the math works; it is whether you can absorb $1,188 to $2,388 upfront, whether your dose and tolerance will remain stable across a year you have not yet lived, and whether a cancellation barrier belongs in a medical decision. For most people starting or switching GLP-1 therapy in 2026, a month-to-month plan with dose-independent pricing and no membership fee offers better risk-adjusted value than prepayment savings that evaporate the moment circumstances change.

At a glance: annual and multi-month GLP-1 plans

All figures checked September 4, 2026. Effective monthly rates are our calculation (upfront ÷ term length); confirm current checkout totals before committing.

What you are actually prepaying for

The advertised savings rest on three distinct models. All-inclusive prepaid plans—Found's cash-pay annual at $169/month and Henry Meds' 12-month semaglutide at $197/month—bundle medication, clinical supervision, and shipping into a single prepaid sum. Program-only prepaid plans—Ro Body Program annual at $74/month, Calibrate Metabolic Reset at $199/month, WeightWatchers Clinic Med+ at $74/month after a promotional period—collect upfront fees for coaching, visits, and care coordination but bill medication separately each month, adding $149 to $449 depending on compound and dose. Membership prepaid plans—PlushCare annual at $12.42/month effective—cover platform access and discount visits but treat medication and labs as separate line items every billing cycle.

The difference matters because prepayment risk concentrates where dollars concentrate. Locking $2,028 into an all-inclusive Found plan means your medication supply, clinical access, and program structure are all frozen for twelve months; changing dose, switching compounds, or discovering intolerance leaves you weighing sunk cost against medical need. Locking $888 into Ro's annual Body Program preserves medication flexibility—you can adjust or stop the drug each month—but commits you to paying the membership fee whether or not you continue treatment. A Calibrate prepayment at $2,388 covers neither medication nor labs, so your true annual cost remains unknown until you add twelve months of prescriptions and diagnostic work.

Normalized 12-month cost analysis

To compare prepaid and flexible options on equal footing, the table below calculates total cash outlay over twelve months under four scenarios: an individual who remains on starting-dose semaglutide for the full year, an individual who titrates semaglutide to maintenance dose, an individual on starting-dose tirzepatide, and an individual who discontinues at month six. Every projection uses documented per-month rates and includes membership fees, medication, and standard clinical access; it excludes labs, copays, and one-time intake charges common to all pathways. These are our calculations derived from the pricing evidence captured September 4, 2026.

All figures our calculation from captured checkout rates (September 4, 2026). Medication costs assume starting dose held constant; real-world titration may increase per-month costs at providers with dose-dependent pricing. "Stop at Month 6" reflects sunk cost for prepaid plans and actual charges paid for month-to-month plans.

The flexibility penalty: what you lose by locking in

Prepayment savings evaporate under three common scenarios. Early discontinuation turns every prepaid plan into a sunk cost: Found's $2,028 annual fee buys twelve months whether you use six or twelve, and Calibrate's $2,388 Metabolic Reset program fee remains due even if medication intolerance or insurance approval ends your need for the service at month four. Dose titration at providers with dose-linked pricing—Ro charges $149/month for Wegovy starting dose and up to $299 at higher doses—means your locked-in program fee covers a shrinking fraction of your total cost as treatment advances, and individuals who reach maintenance dose mid-contract pay peak rates for half the term. Compound switching is structurally easy at month-to-month programs and structurally expensive at prepaid programs: moving from semaglutide to tirzepatide or from injection to oral formulation under a Found annual plan requires either abandoning the remaining prepaid months or running two therapies in parallel until the contract expires.

The table below isolates the penalty for early exit under realistic clinical scenarios, comparing sunk cost at prepaid programs against actual charges paid at flexible programs when treatment stops at month six.

Sunk cost = cash paid that delivers no further benefit if treatment stops. Our calculation from September 4, 2026 rates; confirm refund and cancellation policies before committing.

Liquidity cost and opportunity cost

Prepayment ties capital. An individual committing $2,028 to Found's annual plan or $2,388 to Calibrate's Metabolic Reset surrenders the option to deploy that cash elsewhere—paying down higher-interest debt, covering an unexpected medical expense, or simply preserving three months of living expenses in an emergency fund. The liquidity cost is real even when the prepaid rate delivers nominal savings: saving $100 per month over twelve months produces $1,200 in avoided costs, but the avoided costs accrue across the year while the $2,028 outlay disappears on day one. An individual without $2,000 in discretionary cash flow cannot access the annual discount no matter how attractive the per-month arithmetic, and an individual with $2,000 in discretionary cash flow must decide whether locking that capital into a single healthcare service for twelve months represents the highest-value use.

The opportunity cost compounds when we compare prepaid GLP-1 plans against flexible plans. PlexusDx month-to-month semaglutide injection at $189/month costs $2,268 over twelve months—$240 more than Found's $2,028 annual rate—but the $240 premium buys complete freedom to stop, switch, or adjust without financial penalty. Henry Meds monthly semaglutide at $297/month costs $3,564 annually—$1,200 more than Henry Meds' own 12-month paid-in-full rate at $2,364—but the monthly option eliminates $2,364 in upfront exposure and allows exit at any billing cycle. The question is not whether $240 or $1,200 is trivial; the question is whether eliminating prepayment risk and preserving liquidity is worth $20 or $100 per month to you.

When prepayment makes sense

Prepaid annual plans offer genuine value under three narrow conditions. Established stable dose: an individual already on maintenance semaglutide or tirzepatide for six consecutive months, with no titration, no side effects requiring intervention, and no planned compound switch, faces minimal clinical risk from a twelve-month lock-in. High discretionary liquidity: an individual with at least six months of living expenses in liquid reserves and no competing high-interest debt can absorb the upfront cost without opportunity cost. All-inclusive bundling: programs like Found's cash-pay annual at $169/month effective and Henry Meds' 12-month semaglutide at $197/month effective bundle medication and clinical access into one prepaid sum, eliminating the multi-line-item complexity and separate dose-dependent medication billing that plague Ro, Calibrate, and WeightWatchers annual plans.

Even under ideal conditions, the savings threshold matters. Found's annual plan saves $1,440 over twelve months versus Found's own monthly rate ($2,028 prepaid versus $3,468 paid monthly), a 41% reduction that may justify lock-in risk for individuals meeting all three conditions above. Ro Body Program's annual rate saves $894 versus Ro's monthly program fee ($888 prepaid versus $1,788 paid monthly), but Ro's program fee excludes medication—adding $1,788 to $3,588 annually depending on compound and dose—so the $894 program savings represent only 15–25% of total cost, and the majority of spend remains exposed to dose increases and formulary changes throughout the year. PlushCare's annual membership at $149 saves $90.88 versus monthly membership ($149 prepaid versus $239.88 paid monthly), but PlushCare membership covers only platform access; visits remain $129 each, and medication cost depends entirely on retail or mail-order pharmacy pricing, making the $90.88 annual membership saving irrelevant to individuals whose total GLP-1 cost is driven by $200–$400 monthly prescriptions.

Where PlexusDx fits

PlexusDx operates on a flexible month-to-month model with optional 3-month and 6-month prepaid terms. Semaglutide injection runs $189/month with no commitment, $169/month on a 3-month term, or $149/month on a 6-month term; tirzepatide injection runs $289/month with no commitment, $269/month on a 3-month term, or $249/month on a 6-month term. Every plan charges the same rate at every dose—no step pricing, no surcharge for titration—and includes the prescriber visit, medication, and shipping in a single line item with no separate membership fee. Oral semaglutide ($289 month-to-month, $249 six-month prepaid), oral tirzepatide ($349 month-to-month, $279 six-month prepaid), and microdose GLP-1 maintenance ($129 month-to-month) follow the same structure: transparent per-month pricing, optional short-term prepayment discounts, and the ability to stop or switch without penalty at any billing boundary.

PlexusDx holds a 4.3-star rating on Trustpilot, with 79% of reviews at five stars and 83% at four stars or higher (captured September 9, 2026). The program does not offer a 12-month prepaid option, and individuals seeking to lock in a full-year rate will find steeper nominal discounts at Found ($169/month effective annual versus PlexusDx $189 month-to-month or $149 six-month prepaid) and Henry Meds ($197/month effective annual for semaglutide versus PlexusDx $189 month-to-month or $149 six-month prepaid). PlexusDx six-month semaglutide at $149/month requires $894 upfront and delivers $480 in savings over twelve months versus the month-to-month rate—less than Found's $1,440 annual saving but with half the capital commitment and half the contract duration.

Choose Found annual if…

You have been on stable semaglutide or tirzepatide for at least six months with no side effects, no dose adjustments, and no plans to switch compounds or routes; you have $2,028 in discretionary cash available that is not needed for emergency reserves or higher-interest debt; you value the 41% discount over Found's own monthly rate ($169/month effective versus $289 month-to-month); and you are comfortable accepting that early discontinuation for any reason—medication intolerance, insurance approval for branded therapy, pregnancy, or simply changing your mind—forfeits the remaining prepaid months with no refund. Found's cash-pay annual all-inclusive rate is the lowest per-month GLP-1 cost we documented among programs bundling medication and clinical access, but it is also the largest single upfront commitment and the longest contract lock-in.

Choose Henry Meds 12-month paid-in-full if…

You are committed to injectable semaglutide specifically (Henry Meds offers tirzepatide only as an oral dissolving tablet on a 3-month term, not as an injection and not on a 12-month term), you have $2,364 in discretionary capital, you value the $1,200 saving versus Henry Meds' own $297/month rate, and you can tolerate the fact that stopping at month six leaves $1,182 in sunk cost on the table. Henry Meds carries a 4.4-star Trustpilot rating across approximately 13,000 reviews (captured September 4, 2026). The 12-month paid-in-full semaglutide plan at $197/month effective is $48/month more expensive than Found's annual rate but $40/month cheaper than PlexusDx six-month prepaid semaglutide and $92/month cheaper than PlexusDx month-to-month.

Choose Ro or Calibrate annual if…

You specifically want branded FDA-approved Wegovy or Zepbound rather than compounded semaglutide or tirzepatide, you have insurance prior authorization or are prepared to pay $149–$449 per month for medication on top of the prepaid program fee, and you value the structured coaching and metabolic-reset curriculum enough to commit $888 (Ro Body annual) or $2,388 (Calibrate Metabolic Reset) upfront. Both programs separate the membership/coaching fee from medication cost, so prepaying the program does not lock in medication pricing, does not insulate you from dose-dependent price increases, and does not eliminate the need to manage a separate monthly pharmacy transaction. Calibrate explicitly advertises brand-name GLP-1 injections and positions the Metabolic Reset as a clinical behavior-change program with limited refund terms; Ro's Body Program offers both branded and compounded options but bills them separately from the annual membership. Trustpilot review themes for Ro (captured September 4, 2026) include confusion over the separate membership and medication costs, prior-authorization friction, and customer service complaints. We did not locate a verified Trustpilot profile for Calibrate in the research packet.

Choose PlexusDx if…

You want predictable all-inclusive monthly pricing with the freedom to stop or switch without forfeiting prepaid months, you prefer not to tie $1,200–$2,400 in capital to a single service for six to twelve months, or you are starting GLP-1 therapy for the first time and do not yet know your maintenance dose, tolerance, or compound preference. PlexusDx semaglutide injection at $189/month with no commitment costs $21/month more than Found's annual effective rate but eliminates $2,028 in upfront exposure and allows exit at any month; PlexusDx six-month prepaid semaglutide at $149/month costs $20/month less than Found's annual rate, requires half the upfront capital ($894 versus $2,028), and cuts the contract duration in half. Tirzepatide injection at $289 month-to-month or $249 six-month prepaid, oral semaglutide at $289 month-to-month or $249 six-month prepaid, oral tirzepatide at $349 month-to-month or $279 six-month prepaid, and microdose maintenance at $129 month-to-month give you the option to adjust therapy as your needs evolve without triggering a new annual commitment each time.

Methodology and freshness

This comparison draws on checkout verification, homepage and plan-page review, and Trustpilot sentiment analysis completed September 4, 2026. Pricing for Found, Henry Meds, Hims & Hers, Ro, Calibrate, WeightWatchers Clinic, PlushCare, Noom Med, LifeMD, Mochi Health, Eden, OrderlyMeds, MEDVi, IVIM Health, and Fridays Health was captured from publicly accessible web pages, verified where possible at simulated or actual checkout, and recorded with the access date. Trustpilot profiles were accessed September 4, 2026; individual review themes are reported as anecdotal user accounts and do not represent verified outcomes. All 12-month cost projections, effective monthly rates from prepaid terms, and early-exit penalty calculations are our own arithmetic derived from the documented per-month or per-term rates. PlexusDx pricing reflects the standard rate card published September 8, 2026. Readers should confirm current checkout totals, refund policies, cancellation terms, and medication availability before committing to any prepaid plan.

Frequently Asked Questions

Do annual GLP-1 plans really save money over twelve months?

Yes, if you complete the full term without stopping or switching. Found's annual plan saves $1,440 over its own monthly rate across twelve months, and Henry Meds' 12-month paid-in-full semaglutide plan saves $1,200 versus monthly billing. The savings disappear if you discontinue early, and programs that separate medication from membership fees may show smaller real savings once you add dose-dependent drug costs each month.

What happens if I need to stop my annual GLP-1 plan early?

Most prepaid annual plans do not refund unused months. Found's $2,028 annual fee is paid upfront and non-refundable, so stopping at month six forfeits approximately $1,014 in prepaid value. Calibrate's Metabolic Reset has a limited refund policy, and Ro Body Program annual is prepaid in full. Month-to-month plans let you stop at any billing cycle with no sunk cost.

Can I switch from semaglutide to tirzepatide mid-contract on an annual plan?

Switching mid-contract is structurally difficult on prepaid plans. Found's annual rate covers one compound for twelve months; switching requires either running out the remaining months or starting a separate new plan. Month-to-month programs like PlexusDx, MEDVi, and Henry Meds monthly allow you to switch at the next billing cycle with no penalty and no abandoned prepayment.

Is a 6-month prepaid plan a safer middle ground than a 12-month plan?

Yes, shorter prepaid terms reduce capital commitment and contract duration. PlexusDx six-month prepaid semaglutide at $894 upfront is half the exposure of Found's $2,028 annual plan, and Hims & Hers six-month semaglutide at $1,194 offers lower lock-in risk than any 12-month option. You still forfeit the prepaid amount if you stop early, but the financial penalty is smaller and you reevaluate fit twice as often.

Do programs with separate membership and medication fees really cost less annually?

Not usually. Ro Body Program annual at $888 plus twelve months of Wegovy starting dose at $149/month totals $2,676, only $408 less than Found's $2,028 all-inclusive annual rate that bundles compounded medication, and Ro's cost climbs to $4,476 if you need Zepbound. Calibrate's $2,388 annual program fee excludes medication entirely, pushing total cost above $4,000 for most individuals. All-inclusive prepaid plans concentrate savings; membership-only prepaid plans do not.

Sources

• PlexusDx published pricing (September 8, 2026)
• Found homepage and plan pages (accessed September 4, 2026)
• Henry Meds pricing page and checkout flow (accessed September 4, 2026)
• Hims & Hers weight loss page and checkout verification (accessed September 4, 2026)
• Ro Body Program page and medication pricing (accessed September 4, 2026)
• Calibrate Metabolic Reset program page (accessed September 4, 2026)
• WeightWatchers Clinic Med+ plan page (accessed September 4, 2026)
• PlushCare membership page (accessed September 4, 2026)
• Noom Med pricing page (accessed September 4, 2026)
• LifeMD GLP-1 program page (accessed September 4, 2026)
• Mochi Health pricing page (accessed September 4, 2026)
• Eden pricing and membership structure (accessed September 4, 2026)
• OrderlyMeds pricing page (accessed September 4, 2026)
• MEDVi pricing and checkout verification (accessed September 4, 2026)
• IVIM Health and Fridays Health homepage review (accessed September 4, 2026)
• Trustpilot profiles for Found, Henry Meds, Hims & Hers, Ro, WeightWatchers Clinic, Noom, Mochi Health, Eden, OrderlyMeds, MEDVi (accessed September 4, 2026)
• PlexusDx Trustpilot profile (verified rating 4.3 stars, 79% five-star, 83% four-star or higher; September 9, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.